Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 29, 2026
12:00 PM - 01:00 PM EDT
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Natalie S. Callander, MD
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS
Ghayas Issa, MD
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.